Seung Ki Min

Seung Ki Min

Auto-generated profile, based on publicly available information

Seung Ki Min

Sungkyunkwan University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
SMSeung Ki Min
Seung Ki Min
SLSe Kyung Lee
Se Kyung Lee
JWJinsun Woo
Jinsun Woo
SJSung Mi Jung
Sung Mi Jung
JRJai Min Ryu
Jai Min Ryu
SKSeok Won Kim
Seok Won Kim
Min SK, et al. J Breast Cancer. 2020 Sep;24:e4. https://doi.org/10.4048/jbc.2021.24.e4

22 May 2022 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
SMSeung Ki Min
Seung Ki Min
YYYunghun You
Yunghun You
DCDong Wook Choi
Dong Wook Choi
IHIn Woong Han
In Woong Han
Sang Hyun ShinSang Hyun Shin
Sang Hyun Shin
JHJin Seok Heo
Jin Seok Heo

16 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
SMSeung Ki Min
Seung Ki Min
SOSung Eun Oh
Sung Eun Oh
JAJi Yeong An
Ji Yeong An
HKHyun Kyoon Kim
Hyun Kyoon Kim
EKEun Jin Kim
Eun Jin Kim
MCMin-Gew Choi
Min-Gew Choi
Background: Hemogram is a novel biodegradable powdered hemostatic agent developed by binding calcium ions (Ca² + ) to carboxymethyl starch (CM-starch) and applying granulation technology to enhance blood absorption and hemostatic efficacy. This study aimed to evaluate the clinical efficacy and safety of Hemogram compared with the commercially available agent Arista™ AH in patients undergoing gastrectomy. Methods: This randomized controlled trial was conducted at Samsung Medical Center and included patients who experienced intraoperative oozing-type bleeding during gastrectomy. A total of 64 patients were enrolled and evenly randomized to receive either Hemogram (n = 32) or Arista™ AH (n = 32) for local hemostasis. The primary efficacy endpoint was the hemostatic success rate within 5 min. Secondary endpoints included hemostasis time, re-bleeding rate, number of hemostatic agent units used, transfusion volume, length of hospital stay, and incidence of adverse events. Results: Hemostatic success within 5 min was achieved in 100% (32/32) of the Hemogram group and 96.9% (31/32) of the Arista™ AH group, with no statistically significant difference between the two (P > 0.05). The mean time to hemostasis was 1.25 ± 0.80 min in the Hemogram group and 1.52 ± 0.85 min in the Arista™ AH group. No re-bleeding events were observed in the Hemogram group, while one case of re-bleeding (3.3%) was reported in the Arista™ AH group. There were no significant differences between groups in terms of transfusion volume, length of hospitalization, or adverse event rates. Conclusion: Hemogram demonstrated non-inferior hemostatic efficacy and safety compared to Arista™ AH in patients undergoing gastrectomy. These findings suggest that Hemogram is a promising and clinically applicable hemostatic agent for surgical use.